Sector News

Johnson & Johnson blueprints €125M plant upgrade as part of 5-year Italy investment

June 22, 2024
Life sciences

After plugging nearly 50 million euros into its Italy R&D in the first half of the decade, Johnson & Johnson Innovative Medicine is significantly upping its commitment to the country.

Over the next five years, J&J Innovative Medicine, which recently rebranded from Janssen, will plug a projected 580 million euros ($621.7 million) into its Italian business, the company said in a press release.

Of that sum, 125 million euros will go toward capacity upgrades and a capability buildout at the company’s tablet manufacturing site at Latina in central Italy.

The site, which forms a key piece in J&J’s global supply chain network, produces more than 4 billion tablets each year.

The company’s investment plan is set to boost capacity by more than 25% thanks to the implementation of an automated Flex Line platform to streamline packaging of small batches and a new continuous manufacturing line that J&J says will help slash production timelines.

J&J’s roots in Italy stretch back to 1975. All told, the company employs about 1,370 people in the Mediterranean nation.

Over the past five years, the company has invested nearly 50 million euros in its Italy operations, which much of the outlay going toward R&D. In 2023, J&J Innovative Medicine managed 114 clinical trials and collaborated with nearly 1,000 research centers in Italy.

By Fraiser Kansteiner


comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

How can we help you?

We're easy to reach